Monte Rosa Therapeutics opened lower at $10.17, compared with its previous close of $10.31. In the last trading session, the stock traded between $9.28 and $10.28. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Monte Rosa Therapeutics is now worth
$ 37.73
Resulting in a loss of
$ 62.27 (62.27%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-1.02 (-9.91%)
Day High
$10.28
Day Low
$9.28
Day Open
$10.17
Prev Close
$10.31
Volume
8,92,196
1W Return
-14.05%
1M Return
-11.86%
3M Return
-41.05%
6M Return
-54.16%
1Y Return
-35.14%
Market Cap ($ Mn)
794
PE Ratio
-
PB Ratio
2.34
PEG Ratio
-
ROE
-15.51%
ROCE
-15.34%
EPS (TTM)
$0.04
1 Week
-14.05%
1 Month
-11.86%
3 Months
-41.05%
6 Months
-54.16%
9 Months
-51.01%
Monte Rosa Therapeutics grants inducement equity to five new hires
Monte Rosa Therapeutics granted inducement equity awards to five new non-executive employees. Total awards include 86,725 stock options and 19,150 restricted stock units. Options exercise price set at $11.26, matching Nasdaq closing price on October 1. Grants made under 2026 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
1mo agoMonte Rosa shares slip 6% despite positive MRT-8102 Phase 1 data
Shares fell 6.41% to $11.17 on Thursday, October 1, 2026. MRT-8102 showed 80% to 90% median reduction in NEK7 degradation. hsCRP levels dropped 85% and IL-6 levels fell 54% in trial participants. Phase 2 trials for gout and coronary artery disease planned for early 2027.
1mo agoMonte Rosa grants $14.31 strike price equity awards to six new hires
Monte Rosa granted equity awards to six new non-executive employees. Awards include 31,145 stock options and 6,440 restricted stock units. Exercise price set at $14.31 per share based on Sept 1 closing price. Grants comply with Nasdaq Listing Rule 5635(c)(4) for inducements. Vesting occurs over four years with 25% cliff or annual tranches.
2mo agoMonte Rosa doses first patient in Phase 2 prostate cancer study
Monte Rosa Therapeutics dosed the first patient in MODeFIRe-1 Phase 2 study on Aug. 24, 2026. Trial evaluates MRT-2359 plus apalutamide in mCRPC patients with AR mutations. Study aims to assess PSA response, RECIST response, and radiographic progression-free survival. Updated data from initial Phase 1/2 study expected by end of year.
2mo agoMonte Rosa Therapeutics Q2 Results: Sales Beat Estimates, Losses Widen
Monte Rosa Therapeutics reported Q2 EPS of $(0.43), missing the $(0.38) estimate, while sales of $8.968 million beat the $5.524 million forecast. Sales declined 61.33% YoY from $23.194 million, and losses widened 186.67% YoY from $(0.15).
3mo agoMonte Rosa grants inducement awards to three new employees
Monte Rosa Therapeutics granted inducement equity awards to three newly hired non-executive employees, including non-qualified stock options for 18,025 shares and restricted stock units for 3,900 shares. The awards, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with specific schedules for each award type.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Monte Rosa Therapeutics is now worth
$ 37.73
Resulting in a loss of
$ 62.27 (62.27%)
Note: Past profits do not guarantee future returns.
